New Book Release “Bio-Nanomedicine for Cancer Therapy” edited by Dr. Flavia Fontana and Prof. Hélder Santos

Cancer still remains a societal burden with important psychological and economical implications. Since the approval of the first liposomal formulation of doxorubicin, nanomedicine has been hailed as potential “magic bullet” for the treatment of tumors. However, are traditional nanoparticles really impacting the efficacy of the treatment? Can nanomedicine have a role in the modern cancer treatment world, moving aside for the delivery of chemotherapeutics to include innovative treatment modalities like immunotherapy?
bio-nanomedicine-for-cancer-therapy

The role of nanomedicine in cancer therapy has been heavily investigated, resulting in a complete toolbox for the design of innovative and integrated nanosystems. A biological and immunological approach, together with the bioengineering and material science, is fundamental to integrate targeting, cloaking, and interaction with the immune system.

Dr. Flavia Fontana and Professor Hélder A. Santos, from the Faculty of Pharmacy at the University of Helsinki, proudly edited the recent book “Bio-Nanomedicine for Cancer Therapy”, published by Springer. This book is a toolbox for designing innovative systems in cancer therapy with excellent contributions from top international authors ranging from active targeting and biomimetic coating, to an industrial view on cancer immunotherapy.

The idea behind the book is to provide a useful guide for troubleshooting nanomedicine for the treatment of cancer” says Fontana, “through topic-focused chapters from experts”. Prof. Santos adds.

As the treatment of cancer becomes more and more complex, the “Bio-Nanomedicine for Cancer Therapy” textbook provides up-to-date overview of innovative nanomedicines.

This book is a joint effort of many scientists from all over the world. To them, we are all very grateful for the fantastic contributions.